Novel drug delivery systems

Interest in pain management is growing, with the emerging demand by our patients and colleagues, for pain relief. To meet that need, pharmaceutical and medical technology companies have provided the medical field with a variety of choices and options to deliver medication for pain control. Examination and review of the present systemic options are introduced. A more detailed look at the intrathecal route is necessary because of the tremendous potential for receptor-targeted drug delivery. The ability to treat nociceptive and neuropathic pain with drug-specific therapy makes this system all the more exciting. Because of this future, a wealth of new and old drugs are being found or reexamined for their use.

[1]  Y. Olsson,et al.  Intrathecal and Epidural Somatostatin for Patients with Cancer: Analgesic Effects and Postmortem Neuropathologic Investigations of Spinal Cord and Nerve Roots , 1994, Anesthesiology.

[2]  J. Robinson,et al.  Bioadhesive polymers in peptide drug delivery. , 1990, Biomaterials.

[3]  V. Ranade.  Drug Delivery Systems: 3B. Role of Polymers in Drug Delivery , 1990, Journal of clinical pharmacology.

[4]  N. Rawal.  Spinal antinociception: clinical aspects. , 1995, Annals of medicine.

[5]  P. Bendtsen,et al.  What are the qualities of dilemmas experienced when prescribing opioids in general practice? , 1999, Pain.

[6]  V. Ranade.  Drug Delivery Systems. 6. Transdermal Drug Delivery , 1991, Journal of clinical pharmacology.

[7]  E. Krames,et al.  Clinical realities and economic considerations: patient selection in intrathecal therapy. , 1997, Journal of pain and symptom management.

[8]  K. Leong,et al.  In vitro and in vivo studies of subcutaneous hydromorphone implants designed for the treatment of cancer pain , 1996, Pain.

[9]  Sufentanil citrate and morphine/bupivacaine as alternative agents in chronic epidural infusions for intractable non-cancer pain. , 1991 .

[10]  S. Hassenbusch,et al.  Alternative Intrathecal Agents for the Treatment of Pain , 1999, Neuromodulation : journal of the International Neuromodulation Society.

[11]  R. Lanning,et al.  Intrathecal infusional analgesia for nonmalignant pain: analgesic efficacy of intrathecal opioid with or without bupivacaine. , 1993, Journal of pain and symptom management.

[12]  Wang Di.  Liposomes as a drug delivery system , 1999 .

[13]  D. Rowbotham,et al.  Novel routes of opioid administration. , 1998, British journal of anaesthesia.

[14]  C. Post,et al.  Local Anesthetics Potentiate Spinal Morphine Antinociception , 1988, Anesthesia and analgesia.

[15]  J. Graybill,et al.  Amphotericin B in liposomes: a novel therapy for histoplasmosis. , 1982, The American review of respiratory disease.

[16]  I. Eriator.  Narcotic analgesics for chronic pain management , 1998 .

[17]  S. Cooper,et al.  Anesthetic activity of the lipospheres bupivacaine delivery system in the rat. , 1992, Anesthesia progress.

[18]  V. Ranade.  Drug Delivery Systems: 3A. Role of Polymers in Drug Delivery , 1990, Journal of clinical pharmacology.

[19]  P. Coluzzi.  Cancer pain management: Newer perspectives on opioids and episodic pain , 1998, The American journal of hospice & palliative care.

[20]  E. Zecca,et al.  Pharmacological Treatment of Cancer Pain: Alternative Routes of Opioid Administration , 1998, Tumori.

[21]  S. Einarsson,et al.  Long‐term intrathecal morphine and bupivacaine in “refractory” cancer pain. I. Results from the first series of 52 patients , 1991, Acta anaesthesiologica Scandinavica.

[22]  Eduardo Bruera,et al.  Cancer pain management , 1997, Acta anaesthesiologica Scandinavica.

[23]  D. Goldstein,et al.  Advances in drug delivery and targeting , 1991, Current opinion in oncology.

[24]  V. Ranade.  Drug Delivery Systems—2. Site‐Specific Drug Delivery Utilizing Monoclonal Antibodies , 1989, Journal of clinical pharmacology.

[25]  J. Eisenach.  Three Novel Spinal Analgesics: Clonidine, Neostigmine, Amitriptyline , 1996, Regional Anesthesia & Pain Medicine.

[26]  I. Curelaru,et al.  Continuous Intrathecal Infusion of Opioid and Bupivacaine in the Treatment of Refractory Pain Due to Postherpetic Neuralgia: A Case Report , 1998, Neuromodulation : journal of the International Neuromodulation Society.

[27]  S. Snyder,et al.  Opiate receptor binding in primate spinal cord: distribution and changes after dorsal root section , 1976, Brain Research.

[28]  J. Bianchi,et al.  Epidural administration of liposome-associated bupivacaine for the management of postsurgical pain: a first study. , 1994, Journal of clinical anesthesia.

[29]  P. Wall,et al.  Textbook of pain , 1989 .

[30]  J. Eisenach,et al.  Epidural Clonidine Treatment for Refractory Reflex Sympathetic Dystrophy , 1993, Anesthesiology.

[31]  J. Eisenach,et al.  Epidural clonidine analgesia for intractable cancer pain , 1995, Pain.

[32]  V. Ranade.  Drug Delivery Systems. 1. Site‐Specific Drug Delivery Using Liposomes as Carriers , 1989, Journal of clinical pharmacology.

[33]  Universitd de Louvain.  Increased Selectivity of Drugs by Linking to Carriers , 1978 .

[34]  M. Ashburn,et al.  The Iontophoresis of Fentanyl Citrate in Humans , 1995, Anesthesiology.

[35]  S. Hassenbusch,et al.  Preclinical Toxicity Study of Intrathecal Administration of the Pain Relievers Dextrorphan, Dextromethorphan, and Memantine in the Sheep Model , 1999, Neuromodulation : journal of the International Neuromodulation Society.

[36]  E. Bruera,et al.  Role of rectal route in treating cancer pain: a randomized crossover clinical trial of oral versus rectal morphine administration in opioid-naive cancer patients with pain. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  L. Seigley.  The effects of personal and environmental factors on health behaviors of older adults. , 1998, NursingConnections.

[38]  L. Conrad,et al.  Subarachnoid bupivacaine analgesia for seven months for a patient with a spinal cord tumor. , 1990, Anesthesiology.

[39]  L. Linder,et al.  Epidural versus intrathecal morphine-bupivacaine: assessment of consecutive treatments in advanced cancer pain. , 1990, Journal of pain and symptom management.

[40]  E. Krames.  Intrathecal infusional therapies for intractable pain: patient management guidelines. , 1993, Journal of pain and symptom management.

[41]  Seung-uon Shin,et al.  Chimeric antibody: Potential applications for drug delivery and immunotherapy , 1991, Biotherapy.

[42]  H. Wulf,et al.  The stability of mixtures of morphine hydrochloride, bupivacaine hydrochloride, and clonidine hydrochloride in portable pump reservoirs for the management of chronic pain syndromes. , 1994, Journal of Pain and Symptom Management.

[43]  R. Penn,et al.  Octreotide: a potent new non-opiate analgesic for intrathecal infusion , 1992, Pain.

[44]  H. Benameur,et al.  Toxicity of bupivacaine encapsulated into liposomes and injected intravenously: comparison with plain solutions. , 1993, Anesthesia and analgesia.

[45]  V V Ranade,et al.  Drug Delivery Systems 4. Implants in Drug Delivery , 1990, Journal of clinical pharmacology.

[46]  K. Burchiel,et al.  Intrathecal Opioid Therapy for Pain: Efficacy and Outcomes , 1999, Neuromodulation : journal of the International Neuromodulation Society.